Bruna RochaSócia
Life Sciences & Healthcare
It shows organic and robust growth, driven mainly by digitalization, the globalization of events, and the increased consumption of sports content.
It is an industry that has generated significant revenues, across a diverse range of opportunities in technology, strategic alliances, media, and sponsorships We provide highly specialized and multidisciplinary legal advisory services to companies leading innovation and development in the sector. We work side by side with pharmaceutical industries, biotechnology companies, CROs, medtechs, medical device manufacturers, vaccine developers, healthtechs, healthcare service providers, precision and preventive medicine, and other key players in the sector. Our team combines deep technical and legal knowledge with solid practical experience, understanding the complex regulatory, commercial, and technological nuances that impact each segment By continuously adopting advanced technology, sophisticated sustainability practices, and working proactively to improve patient access to vital products, services, and solutions, this industry occupies an unquestionably relevant position in the global economy
Our view on the industry
The emergence of new technologies is driving the market toward a comprehensive and irreversible metamorphosis. Noteworthy are the rapid advances in digitalization and the emergence of new commercial paradigms in medical technology and the pharmaceutical sector.
Innovative therapies, such as cell and gene therapy, as well as medtechs, are expected to continue generating exciting news in this field. Venture capital remains fundamental to the development of the sector, while collaborative ventures and peer licensing agreements are emerging as promising investment avenues. Meanwhile, market dynamics remain volatile, driven by shifts in capital flows, geopolitics, global inflationary pressures, and economic uncertainties. Sector-specific issues, such as competition for talent, the politicization of drug prices, the judicialization of healthcare, the diversification of clinical trials, and the growing pressure to demonstrate commitment to ESG matters, also make the horizon difficult to see with the necessary clarity.
Even so, the truth is that the coming years hold great potential. We are seeing a growing number of transactions, advances in innovative therapies and medical technologies, and a strategic landscape noteworthy for its B2B collaborations, licensing agreements, and divestitures. An increased focus on contractual arrangements within supply networks further highlights the industry's ethos of resilience. Successfully navigating this dynamic terrain requires skillful maneuvering and experience in the face of constantly evolving challenges.
- China
- Venture capital essential for financing the sector
- Small/mid-sized transactions (rather than mega transactions)
- Divestiture of non-core business assets
- Strategic B2B partnerships
- Regulatory convergence
- Innovative therapies, such as cell and gene therapy
- Generative AI
- Medtechs
- Carbon Market
- High volatility and macroeconomic pressures
- Sustainability
- Financial returns in emerging markets
- Loss of revenue due to patent expiration or generic competition
- Rising R&D costs
- Strict oversight of price controls and the entry of generics or biosimilars
- Judicialization of healthcare
- International Collaboration in Healthcare, with China leading the way
- Patient data interoperability / Real-World Data (RWD)
- Precision Medicine
- Preventive Medicine
- Medtech
- Wearable technology / Health gadgets
Work Highlights
New horizons in gene and oncology therapy research in Brazil
We played a key role in providing specialized guidance to a prominent U.S. biopharmaceutical company, working closely on the development of corporate strategies, the establishment of strategic partnerships, and ensuring regulatory compliance in the innovative gene and oncology therapy clinical trials conducted in Brazil
Expanded access to medicines for rare diseases
As leaders in regulation, we worked on the development of initiatives designed to expand access to medicines for rare diseases on behalf of one of the leading global pharmaceutical companies. We refined market entry strategies, forged strategic alliances, and implemented measures to significantly improve the availability of these vital treatments in Brazil
Defining responsible Generative AI policies
In partnership with a global pharmaceutical giant, we played an important role in formulating ethical and regulatory policies to guide the responsible use of generative artificial intelligence. We sought to ensure regulatory compliance and promote the ethical use of this innovative technology across all of its operations, establishing clear and transparent guidelines
Guiding the deployment of healthcare solutions in Brazil
We facilitated the expansion of a leading infection prevention solutions company in the healthcare sector into the Brazilian market. By providing specialized guidance in areas such as asset acquisition, tax strategies, regulatory compliance, customer management, and operational structuring, we helped ensure a successful and sustainable entry into the local market
Carbon neutrality on behalf of health and well-being
We collaborated with a major investment fund and a Brazilian company committed to the energy transition, health, and well-being. Our work aims to drive the decarbonization journey, developing and implementing innovative programs for the generation and offsetting of carbon credits, aligned with the principles of sustainability and regeneration
Areas of Practice
Get to know our leaders
Register
and receive our content firsthand